Hinge Health (HNGE) Company Report

Analyst Coverage

Research analysts who have asked questions during Hinge Health earnings calls.

Craig Hettenbach

Morgan Stanley

3 questions for HNGE

Also covers: ACCD, AMWL, ARDT +10 more

Elizabeth Anderson

Evercore ISI

3 questions for HNGE

Also covers: AGL, ALGN, CAH +24 more

Jailendra Singh

Truist Securities

3 questions for HNGE

Also covers: ACCD, AGL, AMWL +16 more

Jessica Tassan

Piper Sandler

2 questions for HNGE

Also covers: ACCD, ALHC, AMWL +12 more

Rishi Jaluria

RBC Capital Markets

2 questions for HNGE

Also covers: AKAM, BOX, COUR +21 more

Ryan McDonald

Needham

2 questions for HNGE

Also covers: AMWL, MH, ODD +2 more

Ryan Powderly-Gross

Barclays

2 questions for HNGE

Also covers: ALKT

Scott Schoenhaus

KeyBanc Capital Markets

2 questions for HNGE

Also covers: ALIT, CERT, DOCS +9 more

Stan Berenshteyn

Wells Fargo Securities

2 questions for HNGE

Also covers: AMWL, DOCS, GDRX +4 more

Bradley Sills

Bank of America

1 question for HNGE

Also covers: ADBE, BILL, CRM +14 more

Brian Peterson

Raymond James Financial

1 question for HNGE

Also covers: BIGC, BLKB, BOX +20 more

Richard Close

Canaccord Genuity Group

1 question for HNGE

Also covers: ACCD, AHCO, CLOV +15 more

Ryan Daniels

William Blair & Company, L.L.C.

1 question for HNGE

Also covers: ACCD, AGL, ALHC +12 more

Saket Kalia

Barclays Capital

1 question for HNGE

Also covers: ADBE, ADSK, ALKT +26 more

Latest news

Recent press releases and 8-K filings for HNGE.

Hinge Health Announces Strong Q4 and Full-Year 2025 Results with Positive 2026 Guidance

HNGE

Earnings

Guidance Update

Revenue Acceleration/Inflection

Hinge Health reported strong financial performance for Q4 2025, with $171 million in revenue (up 46% year-over-year) and a 28% non-GAAP operating margin. For the full year 2025, revenue reached $588 million (up 51% year-over-year), alongside a 20% non-GAAP operating margin and $180 million in free cash flow (31% margin).
The company demonstrated significant operational growth, ending 2025 with 24.6 million contracted lives across 2,800+ clients, supported by a 97% annual client retention rate and over 110% net dollar retention.
Hinge Health issued positive guidance, projecting Q1 2026 revenue between $171 million and $173 million, and full-year 2026 revenue of $732 million to $742 million with a 21% non-GAAP operating margin at the midpoint.

Feb 10, 2026, 9:30 PM

Presentation

Hinge Health Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance

HNGE

Earnings

Guidance Update

Share Buyback

Hinge Health reported full year 2025 revenue of $588 million, representing 51% year-over-year growth, with an operating margin of 20% and $180 million in free cash flow (31% margin).
For Q4 2025, the company delivered $171 million in revenue (46% year-over-year growth), an operating margin of 28%, $62 million in free cash flow (36% margin), and diluted net income per share of $0.49.
The company provided full year 2026 revenue guidance of $732 million to $742 million, representing 25% year-over-year growth at the midpoint, and non-GAAP income from operations of $151 million to $156 million (21% margin at midpoint).
Hinge Health announced a share repurchase program of up to $250 million, repurchasing 1.4 million shares for $65 million in Q4 2025.
The company expanded its market reach to nearly 25 million contracted lives and surpassed 100 million lifetime member activity sessions in 2025.

Feb 10, 2026, 9:30 PM

Transcript

Hinge Health Reports Strong Q4 and Full-Year 2025 Results, Provides Optimistic 2026 Guidance

HNGE

Earnings

Guidance Update

Share Buyback

Hinge Health reported Q4 2025 revenue of $171 million, a 46% year-over-year increase, and full-year 2025 revenue of $588 million, up 51% compared to 2024.
The company achieved a full-year 2025 operating margin of 20% and generated $180 million in free cash flow, resulting in an annual free cash flow margin of 31%, meeting its IPO target ahead of schedule.
For full-year 2026, Hinge Health expects revenue between $732 million and $742 million, representing 25% year-over-year growth at the midpoint, and non-GAAP income from operations of $151 million-$156 million, or a 21% margin at the midpoint.
In 2025, the company expanded to nearly 25 million contracted lives across over 2,800 clients, a 24% year-over-year growth, and increased its members to 783,000, a 47% increase from 2024.
Hinge Health's board authorized a share repurchase program of up to $250 million in Q4 2025, with 1.4 million shares repurchased for $65 million during the quarter.

Feb 10, 2026, 9:30 PM

Transcript

Hinge Health Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance

HNGE

Earnings

Guidance Update

Share Buyback

Hinge Health delivered Q4 2025 revenue of $171 million, representing 46% year-over-year growth, and full-year 2025 revenue of $588 million, up 51% compared to 2024.
The company achieved a Q4 2025 operating margin of 28% and a full-year 2025 operating margin of 20%, alongside generating $62 million in free cash flow in Q4 (36% margin) and $180 million for the full year (31% margin).
Hinge Health ended 2025 with approximately 24.6 million contracted lives across over 2,800 clients, marking a 24% year-over-year growth in contracted lives.
For 2026, the company projects Q1 revenue between $171 million and $173 million and full-year revenue between $732 million and $742 million.
In Q4 2025, Hinge Health repurchased 1.4 million shares for $65 million as part of a board-authorized share repurchase program of up to $250 million.

Feb 10, 2026, 9:30 PM

Transcript

Hinge Health Reports Record Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Initiates Share Repurchase

HNGE

Earnings

Guidance Update

Share Buyback

Hinge Health announced record financial results for the quarter and year ended December 31, 2025, with revenue increasing 46% year over year to $170.7 million in Q4 2025 and 51% year over year to $587.9 million for the full year 2025.
The company reported Non-GAAP income from operations of $48.0 million in Q4 2025 and $119.5 million for the full year 2025, a significant improvement from a non-GAAP loss in 2024, and saw free cash flow increase 297% to $179.6 million for the full year 2025.
Hinge Health provided Q1 2026 revenue guidance between $171 million and $173 million and full year 2026 revenue guidance between $732 million and $742 million.
During Q4 2025, the company repurchased $65.0 million in aggregate value of its Class A common stock, following the authorization of a $250.0 million share repurchase program in November 2025.

Feb 10, 2026, 9:07 PM

8-K

Hinge Health Reports Record Q4 and Full Year 2025 Financial Results

HNGE

Earnings

Guidance Update

Revenue Acceleration/Inflection

Hinge Health announced record financial results for the quarter and year ended December 31, 2025, with Q4 2025 revenue increasing 46% year over year to $170.7 million and full year 2025 revenue increasing 51% year over year to $587.9 million.
The company demonstrated strong profitability and cash generation, with Q4 2025 non-GAAP income from operations increasing 124% to $48.0 million and full year 2025 non-GAAP income from operations reaching $119.5 million (compared to a non-GAAP loss in 2024). Full year 2025 free cash flow increased 297% to $179.6 million.
Key metrics as of December 31, 2025, showed significant growth, including a 25% increase in clients to 2,830 and a 47% increase in members to 782,890. The Rule of 40 metric improved to 81 in 2025 from 45 in 2024.
For Q1 2026, Hinge Health expects revenue between $171 million and $173 million, and for full year 2026, revenue is projected to be between $732 million and $742 million.

Feb 10, 2026, 9:05 PM

Press Release

Hinge Health Announces Share Repurchase Program

HNGE

Share Buyback

Hinge Health, Inc. announced a $250 million share repurchase program, authorized by its board of directors on November 10, 2025.
The company intends to fund these repurchases with existing cash and cash equivalents and ongoing cash from operations.
As of the end of Q3 2025, Hinge Health had nearly $500 million in cash and investments and generated $108 million in cash from operations and $118 million in free cash flow during the first three quarters of 2025.

Nov 12, 2025, 2:05 PM

8-K

Hinge Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance

HNGE

Earnings

Guidance Update

New Projects/Investments

Hinge Health reported strong Q3 2025 financial results, with revenue reaching $154 million, representing 53% year-over-year growth, and gross margin improving to 83% from 79% in Q3 last year.
The company achieved a 20% operating margin and generated $81 million in free cash flow, resulting in a 53% free cash flow margin for Q3 2025.
Hinge Health raised its full-year 2025 guidance, now expecting revenue between $572-$574 million and non-GAAP income from operations between $106-$108 million, citing strong business fundamentals and operational efficiency gains from AI initiatives.
Operational highlights include surpassing 1.5 million lifetime members and significant advancements in AI, such as the new Robin AI care assistant and TruMotion computer vision technology for movement analysis. AI initiatives also led to a 120% increase in code output and new features pushed three times faster in Q3 2025 compared to Q3 2024.
A lockup for 77 million shares is scheduled to expire on November 17th, 2025, with shares becoming free to trade on November 18th, 2025.

Nov 4, 2025, 9:30 PM

Transcript

Hinge Health Announces Strong Q3 2025 Results and Updates 2025 Guidance

HNGE

Earnings

Guidance Update

Product Launch

Hinge Health (HNGE) reported Q3 2025 revenue of $154 million, a 53% year-over-year increase, alongside a non-GAAP gross margin of 83% and non-GAAP income from operations of $30 million, representing a 20% operating margin.
The company's client count grew by 25% year-over-year to 2,560, and LTM calculated billings reached $624 million, a 50% year-over-year increase.
For Q4 2025, Hinge Health expects revenue between $155 million and $157 million. The updated full-year 2025 revenue guidance is $572 million to $574 million, reflecting 47% year-over-year growth.
Key product developments include the introduction of Robin AI, a member-facing AI care assistant, and Movement Analysis, which uses AI-motion tracking technology.

Nov 4, 2025, 9:30 PM

Presentation